180 related articles for article (PubMed ID: 37106163)
1. Adapter CAR T cells to counteract T-cell exhaustion and enable flexible targeting in AML.
Nixdorf D; Sponheimer M; Berghammer D; Engert F; Bader U; Philipp N; Kazerani M; Straub T; Rohrbacher L; Wange L; Dapa S; Atar D; Seitz CM; Brandstetter K; Linder A; von Bergwelt M; Leonhardt H; Mittelstaet J; Kaiser A; Bücklein V; Subklewe M
Leukemia; 2023 Jun; 37(6):1298-1310. PubMed ID: 37106163
[TBL] [Abstract][Full Text] [Related]
2. Development of A Chimeric Antigen Receptor Targeting C-Type Lectin-Like Molecule-1 for Human Acute Myeloid Leukemia.
Laborda E; Mazagova M; Shao S; Wang X; Quirino H; Woods AK; Hampton EN; Rodgers DT; Kim CH; Schultz PG; Young TS
Int J Mol Sci; 2017 Oct; 18(11):. PubMed ID: 29077054
[TBL] [Abstract][Full Text] [Related]
3. Tandem bispecific CD123/CLL-1 CAR-T cells exhibit specific cytolytic effector functions against human acute myeloid leukaemia.
Wang XY; Bian MR; Lin GQ; Yu L; Zhang YM; Wu DP
Eur J Haematol; 2024 Jan; 112(1):83-93. PubMed ID: 37712633
[TBL] [Abstract][Full Text] [Related]
4. Combinatorial antigen targeting strategies for acute leukemia: application in myeloid malignancy.
Atilla PA; McKenna MK; Watanabe N; Mamonkin M; Brenner MK; Atilla E
Cytotherapy; 2022 Mar; 24(3):282-290. PubMed ID: 34955406
[TBL] [Abstract][Full Text] [Related]
5. CAR-T cells targeting CLL-1 as an approach to treat acute myeloid leukemia.
Wang J; Chen S; Xiao W; Li W; Wang L; Yang S; Wang W; Xu L; Liao S; Liu W; Wang Y; Liu N; Zhang J; Xia X; Kang T; Chen G; Cai X; Yang H; Zhang X; Lu Y; Zhou P
J Hematol Oncol; 2018 Jan; 11(1):7. PubMed ID: 29316944
[TBL] [Abstract][Full Text] [Related]
6. Systematic preclinical evaluation of CD33-directed chimeric antigen receptor T cell immunotherapy for acute myeloid leukemia defines optimized construct design.
Qin H; Yang L; Chukinas JA; Shah N; Tarun S; Pouzolles M; Chien CD; Niswander LM; Welch AR; Taylor N; Tasian SK; Fry TJ
J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34531250
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of switch-mediated costimulation in trans on universal CAR-T cells (UniCAR) targeting CD123-positive AML.
Meyer JE; Loff S; Dietrich J; Spehr J; Jurado Jiménez G; von Bonin M; Ehninger G; Cartellieri M; Ehninger A
Oncoimmunology; 2021; 10(1):1945804. PubMed ID: 34290907
[TBL] [Abstract][Full Text] [Related]
8. Siglec-6 is a novel target for CAR T-cell therapy in acute myeloid leukemia.
Jetani H; Navarro-Bailón A; Maucher M; Frenz S; Verbruggen C; Yeguas A; Vidriales MB; González M; Rial Saborido J; Kraus S; Mestermann K; Thomas S; Bonig H; Luu M; Monjezi R; Mougiakakos D; Sauer M; Einsele H; Hudecek M
Blood; 2021 Nov; 138(19):1830-1842. PubMed ID: 34289026
[TBL] [Abstract][Full Text] [Related]
9. Prospect of CAR T-cell therapy in acute myeloid leukemia.
Badar T; Manna A; Gadd ME; Kharfan-Dabaja MA; Qin H
Expert Opin Investig Drugs; 2022 Feb; 31(2):211-220. PubMed ID: 35051347
[TBL] [Abstract][Full Text] [Related]
10. Chimeric antigen receptor T-cells targeting IL-1RAP: a promising new cellular immunotherapy to treat acute myeloid leukemia.
Trad R; Warda W; Alcazer V; Neto da Rocha M; Berceanu A; Nicod C; Haderbache R; Roussel X; Desbrosses Y; Daguindau E; Renosi F; Roumier C; Bouquet L; Biichle S; Guiot M; Seffar E; Caillot D; Depil S; Robinet E; Salma Y; Deconinck E; Deschamps M; Ferrand C
J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35803613
[TBL] [Abstract][Full Text] [Related]
11. Novel CAR T therapy is a ray of hope in the treatment of seriously ill AML patients.
Marofi F; Rahman HS; Al-Obaidi ZMJ; Jalil AT; Abdelbasset WK; Suksatan W; Dorofeev AE; Shomali N; Chartrand MS; Pathak Y; Hassanzadeh A; Baradaran B; Ahmadi M; Saeedi H; Tahmasebi S; Jarahian M
Stem Cell Res Ther; 2021 Aug; 12(1):465. PubMed ID: 34412685
[TBL] [Abstract][Full Text] [Related]
12. In Vitro Pre-Clinical Validation of Suicide Gene Modified Anti-CD33 Redirected Chimeric Antigen Receptor T-Cells for Acute Myeloid Leukemia.
Minagawa K; Jamil MO; Al-Obaidi M; Pereboeva L; Salzman D; Erba HP; Lamb LS; Bhatia R; Mineishi S; Di Stasi A
PLoS One; 2016; 11(12):e0166891. PubMed ID: 27907031
[TBL] [Abstract][Full Text] [Related]
13. Bicistronic CAR-T cells targeting CD123 and CLL1 for AML to reduce the risk of antigen escape.
Xie D; Jin X; Sun R; Zhang M; Lu W; Cao X; Guo R; Zhang Y; Zhao M
Transl Oncol; 2023 Aug; 34():101695. PubMed ID: 37224766
[TBL] [Abstract][Full Text] [Related]
14. Optimization of universal allogeneic CAR-T cells combining CRISPR and transposon-based technologies for treatment of acute myeloid leukemia.
Calviño C; Ceballos C; Alfonso A; Jauregui P; Calleja-Cervantes ME; San Martin-Uriz P; Rodriguez-Marquez P; Martin-Mallo A; Iglesias E; Abizanda G; Rodriguez-Diaz S; Martinez-Turrillas R; Illarramendi J; Viguria MC; Redondo M; Rifon J; Villar S; Lasarte JJ; Inoges S; Lopez-Diaz de Cerio A; Hernaez M; Prosper F; Rodriguez-Madoz JR
Front Immunol; 2023; 14():1270843. PubMed ID: 37795087
[TBL] [Abstract][Full Text] [Related]
15. T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia.
Mardiros A; Dos Santos C; McDonald T; Brown CE; Wang X; Budde LE; Hoffman L; Aguilar B; Chang WC; Bretzlaff W; Chang B; Jonnalagadda M; Starr R; Ostberg JR; Jensen MC; Bhatia R; Forman SJ
Blood; 2013 Oct; 122(18):3138-48. PubMed ID: 24030378
[TBL] [Abstract][Full Text] [Related]
16. Safe and effective off-the-shelf immunotherapy based on CAR.CD123-NK cells for the treatment of acute myeloid leukaemia.
Caruso S; De Angelis B; Del Bufalo F; Ciccone R; Donsante S; Volpe G; Manni S; Guercio M; Pezzella M; Iaffaldano L; Silvestris DA; Sinibaldi M; Di Cecca S; Pitisci A; Velardi E; Merli P; Algeri M; Lodi M; Paganelli V; Serafini M; Riminucci M; Locatelli F; Quintarelli C
J Hematol Oncol; 2022 Nov; 15(1):163. PubMed ID: 36335396
[TBL] [Abstract][Full Text] [Related]
17. CD123 redirected multiple virus-specific T cells for acute myeloid leukemia.
Zhou L; Liu X; Wang X; Sun Z; Song XT
Leuk Res; 2016 Feb; 41():76-84. PubMed ID: 26740053
[TBL] [Abstract][Full Text] [Related]
18. CD33-Specific Chimeric Antigen Receptor T Cells with Different Co-Stimulators Showed Potent Anti-Leukemia Efficacy and Different Phenotype.
Li S; Tao Z; Xu Y; Liu J; An N; Wang Y; Xing H; Tian Z; Tang K; Liao X; Rao Q; Wang M; Wang J
Hum Gene Ther; 2018 May; 29(5):626-639. PubMed ID: 29409351
[TBL] [Abstract][Full Text] [Related]
19. [Construction of a new anti-CD123 chimeric antigen receptor T cells and effect of anti-acute myeloid leukemia].
Wang ZZ; Lu Y; Xu YX; Xing HY; Tang KJ; Tian Z; Rao Q; Wang M; Xiong DS; Wang JX
Zhonghua Xue Ye Xue Za Zhi; 2020 Mar; 41(3):192-197. PubMed ID: 32311887
[No Abstract] [Full Text] [Related]
20. Novel adapter CAR-T cell technology for precisely controllable multiplex cancer targeting.
Seitz CM; Mittelstaet J; Atar D; Hau J; Reiter S; Illi C; Kieble V; Engert F; Drees B; Bender G; Krahl AC; Knopf P; Schroeder S; Paulsen N; Rokhvarguer A; Scheuermann S; Rapp E; Mast AS; Rabsteyn A; Schleicher S; Grote S; Schilbach K; Kneilling M; Pichler B; Lock D; Kotter B; Dapa S; Miltenyi S; Kaiser A; Lang P; Handgretinger R; Schlegel P
Oncoimmunology; 2021; 10(1):2003532. PubMed ID: 35686214
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
